WO2014101743A1 - Excipient lyophilisé et son procédé de préparation - Google Patents

Excipient lyophilisé et son procédé de préparation Download PDF

Info

Publication number
WO2014101743A1
WO2014101743A1 PCT/CN2013/090291 CN2013090291W WO2014101743A1 WO 2014101743 A1 WO2014101743 A1 WO 2014101743A1 CN 2013090291 W CN2013090291 W CN 2013090291W WO 2014101743 A1 WO2014101743 A1 WO 2014101743A1
Authority
WO
WIPO (PCT)
Prior art keywords
freeze
binder
suspension
active ingredient
dried excipient
Prior art date
Application number
PCT/CN2013/090291
Other languages
English (en)
Chinese (zh)
Inventor
李和伟
Original Assignee
Li Hewei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Li Hewei filed Critical Li Hewei
Priority to EP13868552.4A priority Critical patent/EP2939664A4/fr
Priority to US14/651,547 priority patent/US20150314004A1/en
Publication of WO2014101743A1 publication Critical patent/WO2014101743A1/fr
Priority to HK16102693.8A priority patent/HK1215667A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates

Definitions

  • the invention relates to a formula and a preparation method of a freeze-dried preparation, in particular to a jelly containing only a binder and an active ingredient, and no skeleton support agent (such as amino acid, sugar, sugar alcohol and inorganic salt) Formulation and preparation method of dry formulation.
  • a skeleton support agent such as amino acid, sugar, sugar alcohol and inorganic salt
  • Freeze-drying technique refers to the addition of a matrix support agent and a binder to a flowable liquid, semi-solid or solid active ingredient, or the flowable liquid, semi-solid or solid itself contains a binder and a skeleton.
  • the support agent is then poured into a molding die, and the process is formed by a freeze-drying process.
  • the formulation prepared by the freeze-drying technique is referred to as a freeze-dried formulation.
  • the heat sensitive component can be protected from being destroyed, and a large number of micropores and pores are generated by sublimation of water, which can have a rapid disintegration and dissolution rate, and thus has been widely used and can be applied to the oral cavity.
  • Traditional freeze-dried shaped preparations consist of a matrix consisting of a matrix and an active ingredient, wherein the matrix comprises a backbone support and a binder, and the backbone support is mostly selected from the group consisting of sugars, sugar alcohols and amino acids of 2 to 12 carbon atoms and inorganic salts (eg Sodium phosphate, aluminum silicate, etc. (see Chinese patents)
  • sugars, sugar alcohols, inorganic salts such as sodium phosphate, aluminum silicate, etc.
  • inorganic salts such as sodium phosphate, aluminum silicate, etc.
  • it is very easy to absorb the moisture in the air during the production process, causing the skeleton structure of the preparation to collapse or completely collapse, or to cause adverse effects, while It also has many defects such as prolonging the disintegration process.
  • the amino acid as a skeleton agent reduces the hygroscopicity, it does not solve the problem fundamentally, and there is no good solution to the cost of the production process.
  • the technical problem to be solved by the present invention is to provide a new tubular formulation containing only a binder and an active ingredient which are not added to the matrix support agent in the process system, and the skeleton support agent includes but is not limited to sugar (such as maltose, trehalose, etc.), sugar alcohols (such as mannitol, sorbitol), amino acids of 2-12 carbon atoms (such as glycine, alanine, glutamic acid, etc.) and inorganic salts (such as sodium phosphate, silicic acid) Aluminum, etc.).
  • sugar such as maltose, trehalose, etc.
  • sugar alcohols such as mannitol, sorbitol
  • amino acids of 2-12 carbon atoms such as glycine, alanine, glutamic acid, etc.
  • inorganic salts such as sodium phosphate, silicic acid
  • the inventor was determined to innovate and carried out a lot of in-depth research and experimental work. It was found that controlling the ratio of binder and active ingredients in the freeze-dried formulation can make the formulation of the freeze-dried formulation not contain the skeleton support agent system. Only the two parts of the binder and the active ingredient can be obtained to obtain a freeze-dried preparation which meets the quality requirements. On the basis of this, other adjuvants such as antioxidants, flavoring agents and flavors, transdermal absorption enhancers, and pH adjusters may be added. By avoiding the use of skeletal support agents, it is possible to reduce the risk of moisture absorption, to reduce the cost of the process, and to increase the technical effect of the unit drug loading.
  • the weight ratio of the binder to the active ingredient may further preferably be 1:90 to 90:1, 1:80 to 80:1, 1:70 to 70:1, 1:60 to 60:1, 1:50 to 50:1, 1:40 to 40:1, 1:30 to 30:1, more preferably 1:20 to 20:1, 1:10 to 10:1, 1:9 to 9:1, 1:8 to 8:1, 1:7 to 7:1, most preferably 1:6 to 6:1, 1:5 to 5:1.
  • the lyophilized formulation provided by the present invention may further comprise other auxiliary materials, such as antioxidants, flavoring agents and flavors, transdermal absorption enhancers, pH adjusters, etc., and the contents of these other auxiliary materials may be prepared by the preparation.
  • the total content of the lyophilized formulation is from 0.1 to 5%, preferably from 0.1 to 3%.
  • the active ingredient may be dissolved in water or insoluble in water, and the active ingredient may be selected from one or one of a chemical pharmaceutical ingredient, a traditional Chinese medicine ingredient, a natural extract, a biological active ingredient, and a skin care benefit component. The combination above.
  • the active ingredient to be used in the present invention is not particularly limited and may be selected from the group consisting of, but not limited to, one or a combination of the following ingredients.
  • Antipyretic analgesic anti-inflammatory drugs such as aspirin, diflunisal, salicylate, acetaminophen, indomethacin, ibuprofen, tea, ketoprofen, pirfen, supprofen, fluoride Biprofen, piroxicam, meloxicam, nimesulide, benzbromarone, etc.;
  • Central stimulants such as pimoline, aprefini, piracetam, etc.
  • migraine drugs such as sumatriptan succinate
  • Analgesics such as rotundin, buprenorphine, pentazocine, naloxone, etc.
  • Anti-Parkinson's disease and treatment of Alzheimer's drugs such as levodopa, compound carbidopa, compound benserazide, amantadine hydrochloride, piracetil, prolamine, donepezil, Huperzine A, etc.
  • Antipsychotic drugs such as chlorpromazine, promethazine, pethidine, thioridazine, cloprofen, clozapine, sulpiride, tiapride, penfluridol, risperidone, etc.;
  • Anti-epileptic and anticonvulsant drugs such as phenytoin, carbamazepine, pumilidone, gabapentin, lamotrigine, sodium valproate, clonazepam, and the like.
  • Sedative hypnotics such as diazepam, nitrazepam, oxazepam, lorazepam, phenobarbital, etc.;
  • a cholinesterase inhibitor such as scopolamine
  • Antiarrhythmic drugs such as propionate, tonicani, mexiletine, ethyl thiazide, phenytoin, propafenone, amiodarone, etc.;
  • Anti-angina and anti-atherosclerotic drugs such as propranolol, nifedipine, gemfibrozil, bezafibrate, lovastatin, simvastatin, pravastatin, etc.;
  • Antihypertensive drugs such as enalapril, captopril, hydrochlorothiazide, amlodipine; adrenal receptor blockers, such as acebutolol, aplol, etc.;
  • Cortic drugs such as betamethasone, cortisone acetate, etc.
  • Antidiabetic drugs such as repaglinide
  • Antithyroid drugs such as propylthiouracil, carbimabazole, methimazole, etc.;
  • Antihistamines such as cetirizine hydrochloride, loratadine, etc.;
  • Autoactive substances such as dinoprostone, alprostadil, betahistine, etc.
  • digestive system drugs such as butyl bromide, granisetron hydrochloride, etc.
  • Blood system drugs such as EPO, adenosine cobalamin, etc.
  • Urinary system drugs such as azosemide, furosemide, etc.
  • Reproductive system drugs such as estrogen, Nandrolone phenylpropionate, etc.
  • Antiparasitic drugs such as albendazole, canbendazole, etc.
  • Antineoplastic agents such as aminoglutethimide, ampicillin, etc.
  • Antimicrobial agents such as ampicillin, sulfacillin sodium, etc.
  • Antibiotics such as amoxicillin, cephalexin, cefprozil, cefuroxime axetil, roxithromycin, erythromycin ethylsuccinate, josamycin, and the like.
  • the active ingredient monomers of traditional Chinese medicine such as: breviscapine, artemisinin, huperzine A, tetrahydropalmatine, etc.;
  • Single-flavored Chinese herbal medicine extract and compound Chinese medicine extract such as: tanshinone extract, salvia miltiorrhiza phenolic acid extract, compound Danshen dripping pill extract, Niuhuang Shangqing pill compound extract, ginseng stem and leaf total saponin, and northern bean root extract , ginseng total saponins, American ginseng total saponins, breviscapine, swollen wind extract, panax notoginseng saponins, capillaris extract, rhubarb extract, andrographolide, hawthorn leaf extract, centella asiatica, ginkgo biloba Extracts, etc.
  • Natural plant extracts such as aloe extract, yam extract, bilberry extract, bitter gourd extract, echinacea extract, feverfew extract, mangosteen extract, pine needle and pine bark extract, Brazilian blackberry extract, mulberry extract , elderberry extract, cranberry extract, astaxanthin, lycopene, green tea extract, grape seed and grape skin extract, licorice, paeoniflorin, licorice flavonoids, paeonol extract, etc.
  • Biologically active ingredients EGF, bFGF, aFGF, KGF, IGF, NGF, TGF, HGH, and the like.
  • Skin care beneficial ingredients vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, coenzymes, proteases, metallothionein, pearls and their hydrolysates, Milk and its extracts, pollen and its extracts, royal jelly, propolis, etc.
  • the binder is an edible or pharmaceutically acceptable water-soluble polymer material, which may be a polysaccharide, a polypeptide, a protein, or an artificially polymerized polymer, or a modified natural high. Molecular materials or mixtures thereof. Commonly used binders include, but are not limited to, gums (collagen, gelatin, hydrolyzed gelatin, gum arabic, xanthan gum, carrageenan, pectin, konjac gum, carrageenan, locust bean gum, gum, locust bean gum).
  • cellulose ethers (carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, etc.), modified starches (pullanose, hydroxypropyl) Base starch, etc., see RPScherer US4305502A), PVP, PVA, hyaluronic acid, albumin, chitosan, dextran, agar, polyamino acid, glycan, and combinations thereof, etc., characterized in that the gum
  • the binder is gelatin, hydrolyzed gelatin, gum arabic, xanthan gum, carrageenan, pectin, konjac gum, carrageenan, locust bean gum, gum, locust bean gum;
  • the agent is carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, etc.;
  • the modified starch type binder is selected from the group consisting of
  • the antioxidant includes, but is not limited to, a mixture of one or more of vitamin C and its derivatives, anthocyanins, resveratrol, and plant-derived polyphenolic compounds;
  • flavoring agents and flavors include, but are not limited to, mint, chocolate, fruit, vanilla, coffee, tea, corn, lemon, milk, etc. or a mixture of one or more of the above;
  • the transdermal absorption enhancer includes, but is not limited to, a mixture of any one or several of lecithin, saponin, sodium lauryl sulphate, azone, tween, and dips;
  • the pH adjusting agent includes, but is not limited to, a mixture of any one or more of citric acid, tartaric acid, carbonate, sodium carbonate, and phosphate.
  • Another aspect of the invention relates to a method of preparing the above lyophilized formulation, the method comprising: I. Preparation of lyophilized excipients without other excipients:
  • the weight ratio of the active ingredient and the binder to water is from 100:1 to 1:100, and further preferably from 1:90 to 90:1, 1:80 to 80:1, 1:70.
  • the liquid injection molding can adopt a pipetting device such as a precise quantitative pipette, a pipetting gun, an electronic pipetting gun, or a plunger pump, a gear pump, a peristaltic pump, etc., and the configured solution, suspension or suspension can be configured.
  • a pipetting device such as a precise quantitative pipette, a pipetting gun, an electronic pipetting gun, or a plunger pump, a gear pump, a peristaltic pump, etc.
  • the liquid is injected into the quantitative forming mold, and the solid injection molding can adopt the precise solid measuring tool and the vibration capillary powder flow controller;
  • the degassing method may adopt a centrifugal degassing method, a vacuum degassing method, an ultrasonic degassing method, etc., wherein the freezing may be performed by liquid nitrogen or liquid, solid carbon dioxide spray cooling or casing circulating cooling device, and the turboexpansion machine In the cooling mode or cascade cooling mode, the solution, suspension or suspension is quickly frozen to a solid at a temperature of -20 ° C to -196 ° C;
  • the lyophilization is carried out using a vacuum of 0.01 to 20 mbar, and the temperature is lyophilized between -70 ° C and 50 ° C. detailed description
  • the invention discloses a freeze-dried forming preparation and a preparation method thereof, and those skilled in the art can learn from the contents of the paper and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
  • the method and the application of the present invention have been described by the preferred embodiments, and it is obvious that the method and application described herein may be modified or appropriately modified and combined without departing from the scope of the present invention. The technique of the present invention is applied.
  • the preparation was placed in a test tube containing 2 ml of 37 ° C water, and the time at which the preparation completely disintegrated and passed through a 20-mesh sieve was observed;
  • the preparation was dropped from a one meter high position to a stainless steel platform in a free fall manner, and 100 pellets were dropped, and the total exfoliated powder was measured, and the weight was less than 3% of the total weight of the preparation.
  • Example 1 The prepared lyophilized formulation was taken out from the bottom of the aluminum nest with a finger, and the preparation was observed.
  • Example 1 The prepared lyophilized formulation was taken out from the bottom of the aluminum nest with a finger, and the preparation was observed.
  • Example 2
  • hyaluronic acid 1: 100, hyaluronic acid lOOmg, 90mg of hyaluronic acid and lmg pearl powder mixed, accurately filled into 0.5ml mold, 10mg hyaluronic acid dissolved in 0.3ml water, perfusion
  • a mold containing 90 mg of hyaluronic acid and 1 mg of pearl powder the water was dispersed in the powder by stirring, frozen to -196 ° C, and lyophilized to become a skin care solid essence.
  • Example 3 Example 3:
  • Example 4
  • PVA 25: 1, acetaminophen 500mg and PVA20mg, infused into 1ml molding die, the mixture is divided into two parts, acetaminophen 500mg powder is filled into 0.6ml molding die, PVA20mg is 0.4ml water Dissolved, infused into 500mg powder, stirred and lyophilized to become acetaminophen drug.
  • Example 11 Example 11:
  • Example 12 Example 12:
  • Aspirin: xanthan gum + pullulan 10:1, aspirin 500mg, xanthan gum 10mg, pullulan 40mg, of which aspirin 500mg perfused into 0.5ml mold, xanthan gum 10mg, pullulan 40mg dissolved in 0.5ml water After dispersion, it is infused into 500 mg of aspirin powder, stirred and lyophilized to become an aspirin drug.
  • Example 1 Test Results Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Disintegration time 5S 5S 3S 15S 15S 15S Appearance smooth and smooth Smooth flat smooth smooth smooth smooth smooth smooth smooth friability ⁇ 3 % ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% Example 7 Example 8 Example 9 Example 10 Example 11 Example 12 Disintegration time 5S 15S 15S 5S 3S 15S Appearance smooth and smooth Smooth flat smooth smooth smooth smooth smooth smooth flat smooth friability ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3% ⁇ 3%

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un excipient lyophilisé et sur un procédé de préparation associé. L'excipient lyophilisé ne comprend qu'un principe actif et un liant et ne comprend pas d'agent support. Le rapport pondéral du principe actif au liant est de 1:100 à 100:1. Le liant est des adhésifs, des éthers de cellulose, des amidons modifiés, de la PVP, un carbomère, du PVA, des acides hyaluroniques, de l'albumine, du chitosane, du dextrane, de la gélose, un polyaminoacide, un glycane ou une association de ceux-ci.
PCT/CN2013/090291 2012-12-26 2013-12-24 Excipient lyophilisé et son procédé de préparation WO2014101743A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP13868552.4A EP2939664A4 (fr) 2012-12-26 2013-12-24 Excipient lyophilisé et son procédé de préparation
US14/651,547 US20150314004A1 (en) 2012-12-26 2013-12-24 Freeze-dried excipient and preparation method thereof
HK16102693.8A HK1215667A1 (zh) 2012-12-26 2016-03-09 種凍干賦型製劑及其製備方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210572660.8A CN103893770B (zh) 2012-12-26 2012-12-26 一种冻干赋型制剂及其制备方法
CN201210572660.8 2012-12-26

Publications (1)

Publication Number Publication Date
WO2014101743A1 true WO2014101743A1 (fr) 2014-07-03

Family

ID=50985550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/090291 WO2014101743A1 (fr) 2012-12-26 2013-12-24 Excipient lyophilisé et son procédé de préparation

Country Status (5)

Country Link
US (1) US20150314004A1 (fr)
EP (1) EP2939664A4 (fr)
CN (1) CN103893770B (fr)
HK (1) HK1215667A1 (fr)
WO (1) WO2014101743A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694221C1 (ru) * 2018-12-14 2019-07-10 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противовоспалительный препарат на основе кетопрофена и способ его получения
EP3329897A4 (fr) * 2015-07-28 2019-07-24 Ling Dong Préparation d'excipient de lyophilisation de forme arbitraire et son procédé de préparation
US11452693B2 (en) 2017-07-12 2022-09-27 Conopco, Inc. Freeze dried active composition and a system for using the same
US11730685B2 (en) 2017-07-12 2023-08-22 Conopco, Inc. Skin composition booster oil

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177973B (zh) * 2014-06-11 2019-10-18 广东东阳光药业有限公司 一种盐酸西替利嗪固体制剂及其制备方法
CN106619539A (zh) * 2015-11-02 2017-05-10 董玲 一种制备任意形状的冻干赋形制剂的方法及其产品
CN107468528A (zh) * 2016-06-07 2017-12-15 董玲 一种冻干制剂及其制备方法
CN106509955B (zh) * 2016-11-10 2018-07-31 东莞市萌创保健科技有限公司 一种免滤纸茶袋包装的冲泡茶片的制备方法
US10149857B2 (en) 2017-03-09 2018-12-11 Ampac Fine Chemicals Llc Lyophilized cyclophosphamide composition and methods of preparation thereof
CN109106736A (zh) * 2017-06-25 2019-01-01 常州伟博海泰生物科技有限公司 一种含有植物组织的冻干赋形制剂
CN111214522A (zh) * 2018-11-23 2020-06-02 山东坦途农业科技有限公司 一种含有三七的冻干赋形制剂及其制备方法
CN111214445A (zh) * 2018-11-23 2020-06-02 山东坦途农业科技有限公司 一种含有矫味剂的三七冻干赋形制剂及其制备方法
CN111214444A (zh) * 2018-11-23 2020-06-02 山东坦途农业科技有限公司 一种含有矫味剂的三七冻干赋形制剂及其制备方法
CN114903809A (zh) * 2021-02-08 2022-08-16 李和伟 一种单一基质冻干赋形制剂及其制备方法、美容护肤冻干制剂
CN112843003A (zh) * 2021-03-25 2021-05-28 海南海灵化学制药有限公司 一种注射用拉氧头孢钠的冻干粉及其冻干工艺

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305502A (en) 1977-07-20 1981-12-15 John Wyeth & Brother Limited Pharmaceutical dosage form packges
CN1475275A (zh) * 2002-12-16 2004-02-18 长春力尔凡药业有限公司 注射用甘露聚糖肽冻干粉针制剂
CN1488343A (zh) * 2002-10-08 2004-04-14 河南省新谊药业股份有限公司 硫普罗宁冻干粉针注射剂
CN1488399A (zh) * 2003-08-14 2004-04-14 忠 吴 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物
CN102302441A (zh) * 2011-09-01 2012-01-04 山东大学 快速冷冻技术制备载药聚合物微纳纤维的方法
CN102614138A (zh) * 2011-01-26 2012-08-01 量子高科（北京）研究院有限公司 一种口腔崩解片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1473315A (en) * 1974-06-10 1977-05-11 Smith W Freeze-dried flavoured pharmaceuticals
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CN101045054A (zh) * 2006-03-29 2007-10-03 上海医药工业研究院 尼莫地平纳米混悬剂冻干组合物、其制备方法及应用
ES2811307T3 (es) * 2009-04-22 2021-03-11 Medskin Solutions Dr Suwelack Ag Composición de principios activos liofilizada
JP5724108B2 (ja) * 2009-04-22 2015-05-27 メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ 凍結乾燥組成物
CN101757030A (zh) * 2010-03-19 2010-06-30 董玲 一种鹿茸全成分均一冻干制剂及其生产方法
CN101984958B (zh) * 2010-11-01 2012-08-08 新疆医科大学第一附属医院 纳米级阿苯达唑微粉及其制备方法
CN102462665B (zh) * 2010-11-18 2016-12-07 董玲 冻干赋形制剂的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305502A (en) 1977-07-20 1981-12-15 John Wyeth & Brother Limited Pharmaceutical dosage form packges
CN1488343A (zh) * 2002-10-08 2004-04-14 河南省新谊药业股份有限公司 硫普罗宁冻干粉针注射剂
CN1475275A (zh) * 2002-12-16 2004-02-18 长春力尔凡药业有限公司 注射用甘露聚糖肽冻干粉针制剂
CN1488399A (zh) * 2003-08-14 2004-04-14 忠 吴 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物
CN102614138A (zh) * 2011-01-26 2012-08-01 量子高科（北京）研究院有限公司 一种口腔崩解片及其制备方法
CN102302441A (zh) * 2011-09-01 2012-01-04 山东大学 快速冷冻技术制备载药聚合物微纳纤维的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2939664A4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3329897A4 (fr) * 2015-07-28 2019-07-24 Ling Dong Préparation d'excipient de lyophilisation de forme arbitraire et son procédé de préparation
US11452693B2 (en) 2017-07-12 2022-09-27 Conopco, Inc. Freeze dried active composition and a system for using the same
US11730685B2 (en) 2017-07-12 2023-08-22 Conopco, Inc. Skin composition booster oil
RU2694221C1 (ru) * 2018-12-14 2019-07-10 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противовоспалительный препарат на основе кетопрофена и способ его получения

Also Published As

Publication number Publication date
EP2939664A4 (fr) 2016-09-14
CN103893770A (zh) 2014-07-02
CN103893770B (zh) 2018-06-19
HK1215667A1 (zh) 2016-09-09
EP2939664A1 (fr) 2015-11-04
US20150314004A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
WO2014101743A1 (fr) Excipient lyophilisé et son procédé de préparation
CN103893133B (zh) 一种冻干赋型制剂的配方及其制备方法
CN104644571B (zh) 一种冻干赋型制剂保护装置及其制备方法
CN101460150B (zh) 用于口腔崩解片剂的可直接压片复合物
WO2014206137A1 (fr) Système d'emballage et de distribution pour excipient lyophilisé et procédé de préparation d'excipient lyophilisé
DK1976562T3 (en) WATER-SOLUBLE MOVIES INCLUDING LOW-VISCITY ALGINATES
WO2015032319A1 (fr) Système d'emballage et de distribution de formulation d'excipient lyophilisée et procédé de préparation
CN106551804B (zh) 一种使用滚模制备冻干赋形制剂的方法及其产品
WO2018028531A1 (fr) Préparation lyophilisée et son procédé de préparation
CN104644568A (zh) 一种含有活性成分及粘结剂的冻干赋型制剂保护装置及其制备方法
BRPI0616784A2 (pt) composições farmacêuticas orais contendo um agente indutor de salivação
CN106963737A (zh) 一种易崩解的任意形态冻干成型制剂及其制备方法
CN106466228A (zh) 一种多模具制备任意形状的冻干赋形制剂的方法及其产品
WO2017016506A1 (fr) Préparation d'excipient de lyophilisation de forme arbitraire et son procédé de préparation
CN106821770A (zh) 一种制备任意形状的冻干制剂的方法及其产品
CN108066152A (zh) 一种冻干赋形制剂的制备方法
CN107280979A (zh) 一种制备任意形状的冻干制剂的方法及其产品
CN107260557A (zh) 一种滚模法制备冻干制剂的方法及其产品
CN205274216U (zh) 一种固液分离即配即用的包装装置
CN106619539A (zh) 一种制备任意形状的冻干赋形制剂的方法及其产品
ES2221840T3 (es) Composicion o estructura microporosa expandida isotropa de disolucion rapida para uso farmaceutico, veterinario, dietetico, alimenticio o cosmetico y su procedimiento de obtencion.
CN106881028B (zh) 一种冻干制剂溶解装置
CN104648834A (zh) 一种含有骨架支持剂及粘结剂的冻干赋型制剂保护装置及其制备方法
CN109106690A (zh) 一种含有骨架支持剂及粘结剂的冻干赋型制剂保护装置及其制备方法
RoshanRai et al. Fast dissolving tablets: A novel approch to drug delivery–A Review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13868552

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14651547

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013868552

Country of ref document: EP